Market Place
Sourcing Support
Axsome Therapeutics Presents Neuroscience Data at NEI 2024
08 Nov 2024 //
GLOBENEWSWIRE
Axsome Present Data from Neuroscience Portfolio at Psych Congress
29 Oct 2024 //
GLOBENEWSWIRE
Axsome Therapeutics To Report Q3 2024 Financial Results
15 Oct 2024 //
GLOBENEWSWIRE
Axsome Presents Data from Multiple Programs at Sleep Europe 2024
24 Sep 2024 //
GLOBENEWSWIRE
FDA Accepts Axsome`s AXS-07 NDA Resubmission For Migraine
04 Sep 2024 //
GLOBENEWSWIRE
Axsome Therapeutics to Participate in Investor Conferences in September
27 Aug 2024 //
GLOBENEWSWIRE
Axsome Settles Sunosi Patent Litigation With Sandoz
21 Aug 2024 //
GLOBENEWSWIRE
Axsome Therapeutics Reports Q2 2024 Results And Business Update
05 Aug 2024 //
GLOBENEWSWIRE
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
11 Jul 2024 //
GLOBENEWSWIRE
Axsome: Settles Sunosi Patent Litigation With Unichem
05 Jun 2024 //
GLOBENEWSWIRE
Axsome: Highlights Unmet Migraine Needs With American Migraine Foundation
04 Jun 2024 //
GLOBENEWSWIRE
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
03 Jun 2024 //
GLOBENEWSWIRE
Axsome Therapeutics to Participate in Upcoming Investor Conferences
30 May 2024 //
GLOBENEWSWIRE
Axsome Highlights Solriamfetol Cognitive Benefit Data At SLEEP 2024
29 May 2024 //
GLOBENEWSWIRE
Axsome: Multiple Program Data At ASCP 2024 Annual Meeting
28 May 2024 //
GLOBENEWSWIRE
Axsome Therapeutics to Present at Upcoming Investor Conferences
08 May 2024 //
GLOBENEWSWIRE
Axsome Reports Q1 2024 Results, Provides Business Update
06 May 2024 //
GLOBENEWSWIRE
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
01 May 2024 //
GLOBENEWSWIRE
Axsome Highlights Neuroscience Portfolio At AAN 2024
15 Apr 2024 //
GLOBENEWSWIRE
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
10 Apr 2024 //
GLOBENEWSWIRE
Axsome Initiates Ph 3 Trial of Solriamfetol for Binge Eating Disorder
01 Apr 2024 //
GLOBENEWSWIRE
Axsome drug succeeds in narcolepsy symptoms trial
26 Mar 2024 //
BIOPHARMADIVE
Axsome Announces Results of CRESCENDO Narcolepsy Patient Survey
25 Mar 2024 //
GLOBENEWSWIRE
Axsome Initiates PARADIGM Ph3 Trial of Solriamfetol for the Treatment MDD
19 Mar 2024 //
GLOBENEWSWIRE
Axsome Therapeutics to Present at Leerink Partners Global Biopharma Conference
05 Mar 2024 //
GLOBENEWSWIRE
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
27 Feb 2024 //
GLOBENEWSWIRE
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
GLOBENEWSWIRE
Axsome Tumbles On An Unexpected Setback For Its Alzheimer`s Drug
01 Feb 2024 //
PRESS RELEASE
Axsome to Report Fourth Quarter and Full Year 2023 Financial Results
23 Jan 2024 //
GLOBENEWSWIRE
Axsome Provides Fourth Quarter and Full Year 2023 Net Revenue
04 Jan 2024 //
GLOBENEWSWIRE
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity
11 Dec 2023 //
GLOBENEWSWIRE
Axsome Hosts Solriamfetol Investor Event with Expert Thought Leaders Today
07 Dec 2023 //
GLOBENEWSWIRE
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
22 Nov 2023 //
GLOBENEWSWIRE
Axsome to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Axsome to add nearly 100 Auvelity sales reps to workforce
06 Nov 2023 //
FIERCE PHARMA
Axsome Therapeutics and the Global Alzheimer™s Disease Community Come Together
02 Nov 2023 //
GLOBENEWSWIRE
Axsome Therapeutics to Present at Upcoming Investor Conferences
31 Oct 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05
24 Oct 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
11 Oct 2023 //
GLOBENEWSWIRE
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
10 Oct 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Joins the National Alliance on Mental Illness
02 Oct 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Joins the Global Narcolepsy Community
21 Sep 2023 //
GLOBENEWSWIRE
Axsome Highlights Commitment to Innovating Treatments for Mental Health
07 Sep 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
12 Jul 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol
07 Jul 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Announces Closing of Public Offering of $225 M of Shares
30 Jun 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million
28 Jun 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
27 Jun 2023 //
GLOBENEWSWIRE
Axsome reports delay to PhIII narcolepsy study
15 Jun 2023 //
ENDPTS
Axsome Therapeutics to Present New Sunosi Data at SLEEP 2023
01 Jun 2023 //
GLOBENEWSWIRE
Axsome to Present Data and Post-Hoc Analyses on Auvelity® & Sunosi® at the 2023
30 May 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Reports 1Q 2023 FYR and Corporate Update
08 May 2023 //
GLOBENEWSWIRE
Axsome Therapeutics to Present at the Bank of America Securities 2023 Conference
03 May 2023 //
GLOBENEWSWIRE
Axsome Therapeutics Joins Mental Health America and the State of New York
01 May 2023 //
GLOBENEWSWIRE
Axsome to Present 5 Abstracts Including New Data +ve SHARP Study of SUNOSIÂ
21 Apr 2023 //
GLOBENEWSWIRE
Axsome to Present at the 22nd Annual Needham Virtual Healthcare Conference
14 Apr 2023 //
GLOBENEWSWIRE
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
13 Apr 2023 //
GLOBENEWSWIRE
Axsome Therapeutics to Present at Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
